| Followers | 2754 |
| Posts | 77901 |
| Boards Moderated | 1 |
| Alias Born | 05/10/2007 |
Saturday, September 14, 2019 1:30:52 PM
Here was my share issuance worksheet for DCGD....I dont see anywhere that one old ex employee got 6 million shares. It looks like Steve Ross and Donald Ross got most or all of those 74m shares. If they cashed in 6m shares last week, what's to stop them from cashing out the other 68m shares???
1.5M FLOAT S1 2010
1 FOR 15 FS 2011 FLOAT 22,500,000
As of March 8, 2013, there were 55,527,641
30M SHARES DONALD ROSS for debt. 2m shares x 15 for foward split
20M On July 19, 2013, Discovery Gold Corporation, a Nevada corporation (the “Company”) and Steven Ross entered into a Loan Conversion Agreement pursuant to which the parties agreed to convert loans from Steven Ross in an aggregate amount of $30,000 plus the accrued interest of $1,134.25 into 7,783,562 restricted shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) and a eighteen-month warrant to purchase 3,750,000 shares of Common Stock at an exercise price of $0.02 per share.
On July 19, 2013, the Company entered into a subscription agreement with Steven Ross whereby it sold 12,500,000 units (the “Units”) of its securities for $50,000. Each of the Units was sold at a purchase price of $0.004 per Unit. Each Unit consists of (i) one share of Common Stock and (ii) one warrant to purchase 0.5 share of Common Stock at a per share exercise price of $0.02.
DONALD ROSS
On April 2, 2015, we issued 18,600,000 shares of our common stock valued at $53,660 in settlement of certain liabilities outstanding, including 4,200,000 shares of common stock valued at $13,020 to a director of ours.
DONALD ROSS
On April 6, 2015 we issued 8,400,000 shares of our common stock valued at $36,660 as fees to a director of ours and to our largest shareholder at that time.
DONALD ROSS
17,500,000 shares of common stock issued to acquire Discovery Ghana Gold Limited
THESE SHARES WERE BOUGHT BY JUSTIN
On April 13, 2018, we issued 69,500,000 shares of our common stock valued at $90,350 to a current director and officer of ours in settlement of the substantial majority of his accrued compensation.
On April 13, 2018, we issued 69,500,000 shares of our common stock valued at $90,350 to a former director and officer of ours in settlement of the substantial majority of his
1.5M FLOAT S1 2010
1 FOR 15 FS 2011 FLOAT 22,500,000
As of March 8, 2013, there were 55,527,641
30M SHARES DONALD ROSS for debt. 2m shares x 15 for foward split
20M On July 19, 2013, Discovery Gold Corporation, a Nevada corporation (the “Company”) and Steven Ross entered into a Loan Conversion Agreement pursuant to which the parties agreed to convert loans from Steven Ross in an aggregate amount of $30,000 plus the accrued interest of $1,134.25 into 7,783,562 restricted shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) and a eighteen-month warrant to purchase 3,750,000 shares of Common Stock at an exercise price of $0.02 per share.
On July 19, 2013, the Company entered into a subscription agreement with Steven Ross whereby it sold 12,500,000 units (the “Units”) of its securities for $50,000. Each of the Units was sold at a purchase price of $0.004 per Unit. Each Unit consists of (i) one share of Common Stock and (ii) one warrant to purchase 0.5 share of Common Stock at a per share exercise price of $0.02.
DONALD ROSS
On April 2, 2015, we issued 18,600,000 shares of our common stock valued at $53,660 in settlement of certain liabilities outstanding, including 4,200,000 shares of common stock valued at $13,020 to a director of ours.
DONALD ROSS
On April 6, 2015 we issued 8,400,000 shares of our common stock valued at $36,660 as fees to a director of ours and to our largest shareholder at that time.
DONALD ROSS
17,500,000 shares of common stock issued to acquire Discovery Ghana Gold Limited
THESE SHARES WERE BOUGHT BY JUSTIN
On April 13, 2018, we issued 69,500,000 shares of our common stock valued at $90,350 to a current director and officer of ours in settlement of the substantial majority of his accrued compensation.
On April 13, 2018, we issued 69,500,000 shares of our common stock valued at $90,350 to a former director and officer of ours in settlement of the substantial majority of his
Recent MAJI News
- NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist • GlobeNewswire Inc. • 05/11/2026 03:53:17 PM
- NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test • GlobeNewswire Inc. • 04/07/2026 02:30:00 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/30/2026 04:15:02 AM
- Form 253G1 - • Edgar (US Regulatory) • 03/27/2026 07:12:08 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/26/2026 08:25:15 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/20/2026 08:23:33 PM
- Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value • GlobeNewswire Inc. • 03/16/2026 02:15:00 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/11/2026 07:11:39 PM
- Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions • GlobeNewswire Inc. • 03/05/2026 06:00:20 PM
- Form 1-A POS - • Edgar (US Regulatory) • 02/19/2026 09:39:04 PM
- Form 253G2 - • Edgar (US Regulatory) • 02/11/2026 08:06:08 PM
- Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition • GlobeNewswire Inc. • 02/10/2026 03:30:00 PM
- Form 253G2 - • Edgar (US Regulatory) • 01/15/2026 06:47:01 PM
- Form 253G1 - • Edgar (US Regulatory) • 01/14/2026 09:54:45 PM
- Form 1-A POS - • Edgar (US Regulatory) • 12/31/2025 12:32:47 PM
- Form 253G2 - • Edgar (US Regulatory) • 12/29/2025 08:29:49 PM
- Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization • ACCESS Newswire • 12/11/2025 05:15:00 PM
- Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement • ACCESS Newswire • 12/05/2025 04:00:00 PM
- Form 253G2 - • Edgar (US Regulatory) • 12/04/2025 09:35:28 PM
- Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms • ACCESS Newswire • 12/02/2025 06:45:00 PM
- Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value • ACCESS Newswire • 11/17/2025 08:40:00 PM
- Exousia Pro Announces Breakthrough In Exosome-Based Delivery • ACCESS Newswire • 11/04/2025 03:40:00 PM
- Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA • ACCESS Newswire • 10/28/2025 02:20:00 PM
- Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes • ACCESS Newswire • 09/29/2025 04:35:00 PM


